Medtide Inc. Announces Acceptance of H Share Full Circulation Plan Application by China Securities Regulatory Commission

Reuters
07/27
Medtide Inc. Announces Acceptance of H Share Full Circulation Plan Application by <a href="https://laohu8.com/S/601066">China Securities</a> Regulatory Commission

Medtide Inc., a joint stock company incorporated in the People's Republic of China, has announced that the China Securities Regulatory Commission (CSRC) has accepted its application for the H Share Full Circulation Plan. This regulatory acceptance pertains to the conversion of 68,201,112 unlisted shares into H shares, each with a par value of RMB1.0. This development is a significant step towards the proposed implementation of the full circulation of H shares for certain shareholders of the company. The conversion and listing process will still require adherence to additional procedures mandated by the CSRC, the Hong Kong Stock Exchange, and other relevant regulatory authorities. Medtide Inc. has advised shareholders and potential investors to exercise caution when dealing in the company's securities. Further announcements will be made as details of the conversion and listing are finalized.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtide Inc. published the original content used to generate this news brief on July 27, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10